Pregnancy following Renal Transplantation

1979 ◽  
Vol 72 (11) ◽  
pp. 815-817 ◽  
Author(s):  
V Parsons ◽  
M Bewick ◽  
J Elias ◽  
S A Snowden ◽  
M J Weston ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Renal Transplant ◽  
Caesarean Section ◽  
Spontaneous Abortion ◽  
Rejection Episode ◽  
Elective Caesarean Section ◽  
The Other ◽  
Transplant Patients ◽  
The Mean ◽  
Renal Transplant Patients

A series of 7 renal transplant patients with 9 pregnancies is reported. A spontaneous abortion at 10 weeks was the only major problem. Of the other 8 pregnancies, 6 were delivered per vaginam and 2 by elective caesarean section, all after 34 weeks. The birthweights were slightly under the mean for the patients’ age but had been made up to normal by three months. Only one rejection episode occurred during pregnancy. Mild rejection episodes occurred in 4 patients within two months following delivery.

Mycophenolate mofetil, an inhibitor of inosine monophosphate dehydrogenase, causes a paradoxical elevation of GTP in erythrocytes of renal transplant patients

2004 ◽  
Vol 107 (1) ◽  
pp. 63-68 ◽  
Author(s):  
David GOLDSMITH ◽  
Elizabeth A. CARREY ◽  
Stephen EDBURY ◽  
Ryszard T. SMOLENSKI ◽  
Piotr. JAGODZINSKI ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Renal Transplantation ◽  
Renal Transplant ◽  
Plasma Metabolites ◽  
Renal Transplant Recipients ◽  
Inosine Monophosphate Dehydrogenase ◽  
Inosine Monophosphate ◽  
Transplant Patients ◽  
Renal Transplant Patients ◽  
Monophosphate Dehydrogenase

The immunosuppressant MMF (mycophenolate mofetil) has increasingly replaced AZA (azathioprine) in renal transplantation. MMF is a prodrug of MPA (mycophenolic acid), which inhibits lymphocyte IMPDH (inosine monophosphate dehydrogenase), thereby drastically decreasing GTP concentrations essential to lymphocyte proliferation in vitro and in vivo. Erythrocyte GTP concentrations are commonly elevated in severe renal disease, but normalize following successful engraftment. Consequently, elevated GTP in renal transplant recipients might signal impending loss of immunosuppression and graft failure. In the present study, we compared erythrocyte nucleotides and plasma metabolites in two groups of 25 patients after renal transplantation, both receiving prednisolone and cyclosporin A, but one group receiving MMF and the other AZA. No patients had recent allograft biopsy evidence of rejection. Erythrocyte GTP concentrations at MMF commencement were 50.4±23.4 μmol/l. An increase occurred during the first 3 months after transplant when MMF was used de novo, stabilizing at 146.7±62.9 μmol/l after 4 months. This was significantly higher (P=2.5×10−6) than erythrocyte GTP (40.4±15.9 μmol/l) in the AZA group, which was essentially unchanged from values immediately after successful transplantation. The effect of MMF on erythrocyte GTP levels was reversible, since GTP levels fell when MMF therapy was terminated. The results demonstrate paradoxically high GTP concentrations in erythrocytes of renal transplant patients receiving MMF. MPA may stabilize reticulocyte IMPDH, allowing the protein to persist during erythropoiesis. This behaviour is in marked contrast with the decrease in GTP levels seen in white blood cells of patients on chronic MMF therapy.

Transplantations: Implications of the Renal Transplantation Process for Rehabilitation Counselors

1993 ◽  
Vol 24 (1) ◽  
pp. 34-37
Author(s):  
Rick Houser ◽  
Varda Konstam
Keyword(s):  
Renal Transplantation ◽  
Chronic Illness ◽  
Renal Transplant ◽  
Functional Limitations ◽  
Rehabilitation Counselors ◽  
Rehabilitation Counselor ◽  
Transplant Patients ◽  
The Family ◽  
Renal Transplant Patients

Renal transplantation is one of the most common forms of transplantation performed today. The rehabilitation counselor may provide an important role in the rehabilitation of persons that have gone through renal transplantation. For example, the rehabilitation counselor can provide information on the effects of experiencing a chronic illness and provide information on the changes in the family as a result of the chronic illness. However, if the rehabilitation counselor is to be helpful to renal transplant patients they must be knowledgeable about the renal transplantation process. In this article we address the renal transplantation process including: the medical aspects, functional limitations, psychological implications and finally vocational implications as they relate to the rehabilitation counselor.

P0126RENAL TRANSPLANT PATIENTS UNDER CALCINEURIN INHIBITOR THERAPY RAPIDLY ACQUIRE AN ABERRANT LYSOSOMAL LESION IN PROXIMAL TUBULAR CELLS

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Benjamin Vervaet ◽  
Nika Kojc ◽  
Cynthia Nast ◽  
Gerd Schreurs ◽  
Patrick D'Haese ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Renal Transplant ◽  
Renal Allograft ◽  
Calcineurin Inhibitor ◽  
Deceased Donor ◽  
Inhibitor Therapy ◽  
Transplant Patients ◽  
Protocol Biopsies ◽  
Proximal Tubular ◽  
Renal Transplant Patients

Abstract Background and Aims Calcineurin inhibitor therapy has changed the field of (renal) transplantation by considerably prolonging graft survival. Yet, all immunosuppressive calcineurin inhibitors are nephrotoxic that eventually contribute to complete scarring of the renal allograft. In renal biopsy analysis many histopathological features have been considered indicative of CNI nephrotoxicity, i.e. striped fibrosis, vascular hyalinosis, isometric tubular vacuolization, glomerulosclerosis, cellular infiltration and tubular atrophy, however, all are rather aspecific and can be secondary to many other causes. During the course of evaluating the specificity of a recently discovered proximal epithelial lysosomal lesion (i.e. multiple enlarged (>1,2µm) dysmorphic lysosomes containing dispersed electron dense non-membrane bound aggregates) in patients with Chronic Interstitial Nephropathy in Agricultural Communities (CINAC), we observed it to be present in renal transplant patients treated with cyclosporine or tacrolimus. Here, we test the hypothesis whether this lysosomal lesion is acquired during CNI therapy. Method A retrospective transmission electron microscopic analysis was performed to evaluate the presence of the typical lysosomal lesion on the following biopsies from renal transplant patients: 20 deceased donor implantation biopsies; 5 living donor implantation biopsies. For another 10 additional deceased donor renal allograft recipients, we evaluated implantation as well as protocol biopsies taken after 6 and 12 months of CNI treatment that started immediately after transplantation. Also included were 24 indication biopsies of CNI treated renal transplants. Results Of the total set of implantation biopsies (n=35), 2 (6%) were positive for the aberrant lysosomal phenotype on EM, whereas in the protocol and indication biopsies prevalence of the lesion was considerably higher ranging between 56% (protocol) and 80% (indication) of cases. Conclusion CNI therapy is associated with the fairly rapid appearance of a particular proximal tubular lysosomal phenotype observable on EM, that was not (or rarely) present at implantation. Whether this lesion is related to CNI toxicity and indicative for the outcome for the graft and/or patient survival after renal transplantation has to be investigated in a prospective trial.

scholarly journals VALGANCICLOVIR INDUCED THROMBOCYTOPENIA: A CASE REPORT

2017 ◽  
Vol 10 (7) ◽  
pp. 3 ◽  
Author(s):  
Amita D ◽  
Balaji O ◽  
Navin Patil
Keyword(s):  
Case Report ◽  
Renal Transplantation ◽  
Renal Transplant ◽  
Adverse Effects ◽  
Transplant Patient ◽  
Hematological Toxicity ◽  
Severe Immunosuppression ◽  
Platelet Counts ◽  
Transplant Patients ◽  
Renal Transplant Patients

Triple immunosuppression is very pivotal in maintaining the graft in case of renal transplantation. But because of severe immunosuppression, always there is chance of severe adverse effects. Hematological toxicity is usually very common but dreaded in case of renal transplant patients. Here, we report a case of valganciclovir-induced drop in platelet counts in a postrenal transplant patient.

scholarly journals P1723CLINICAL AND LABORATORY CHARACTERISTICS OF RENAL TRANSPLANT PATIENTS WITH AA AMYLOIDOSIS IN A TERTIARY CENTER IN TURKEY

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Ece Bilgic ◽  
Rezzan Eren Sadioğlu ◽  
Şahin Eyüpoğlu ◽  
Akın fırat Kocaay ◽  
ACAR TUZUNER ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Clinical Laboratory ◽  
Aa Amyloidosis ◽  
Transplant Patients ◽  
Predictive Parameters ◽  
Tertiary Center ◽  
Insufficient Response ◽  
Mediterranean Fever ◽  
The Mean ◽  
Renal Transplant Patients

Abstract Background and Aims Despite improved therapeutic regimens, AA amyloidosis is still associated with higher risk of mortality after renal transplantation (RT). Moreover the clinical, laboratory characteristics and prognostic factors remain poorly understood. We aimed to identify predictive parameters of prognosis, investigate the etiology, clinical and laboratory features of renal transplant patients with biopsy proven AA amyloidosis. Method We conducted a retrospective study using twenty-eight renal transplant patients with AA amyloidosis and twenty-eight renal transplant control patients without amyloidosis matched for age and time after transplantation that were regularly followed in University of Ankara School of Medicine Nephrology Department between October 2018-October 2019. Causes of AA amyloidosis, treatment (colchicine and/ or anti-interleukin (IL) 1 treatment) and number of Familial Mediterranean Fever (FMF) attacks in the last year in case of FMF, biochemical values such as mean CRP, hemoglobin, serum albumin, proteinuria, glomerular filtration rate (GFR), serum creatinine levels were compared between groups. Results In amyloidosis and non-amyloiodosis group, the mean age was 44±13 and 44±12 years; 57% and 54% were males, mean time after transplantation was 95±64 and 93±12 month, respectively. FMF was found as the most common cause of AA amyloidosis (86%). All FMF patients received colchicine and eight (33%) FMF patients with AA amyloidosis with insufficient response to colchicine were treated with anti-IL-1 agents. The mean colchicine dose was 0,92±0,34 mg/day. The mean GFR were 63±24 ml/dk/1,73 m2 in amyloidosis and 71±19 ml/dk/1,73 m2 in non amyloidosis group, (p=0.195). The most important finding of present study was significantly higher CRP levels in patients with AA amyloidosis compared to non-amyloidosis group (15,12±15,16 mg/L vs 6,59±8,20 mg/L, p=0,011, respectively). Conclusion In this study, we found higher CRP levels in renal transplant patients with AA amyloidosis which indicates persistent ongoing chronic inflammation among these patients. Figure Clinical and Laboratory Characteristics of Patient Groups

Plasma 25-Hydroxy-Vitamin D in Normal Subjects and Patients with Terminal Renal Failure, on Maintenance Haemodialysis and after Transplantation

1979 ◽  
Vol 57 (5) ◽  
pp. 473-476 ◽  
Author(s):  
J. B. Eastwood ◽  
A. Daly ◽  
G. D. Carter ◽  
J. Alaghband-Zadeh ◽  
H. E. De Wardener
Keyword(s):  
Vitamin D ◽  
Renal Failure ◽  
Renal Transplant ◽  
Normal Subjects ◽  
Maintenance Haemodialysis ◽  
Terminal Renal Failure ◽  
Transplant Patients ◽  
25 Hydroxy Vitamin D ◽  
The Mean ◽  
Renal Transplant Patients

1. Plasma 25-hydroxy-vitamin D concentration was measured in 40 normal subjects, 19 patients with terminal renal failure, 137 patients who had been on dialysis up to 11 years and in 17 renal transplant patients. 2. The mean plasma concentration of 25-hydroxy-vitamin D was below normal in patients with terminal renal failure and in patients who had been on maintenance haemodialysis for less than 1 year. The mean concentration in patients who had been on dialysis for more than 1 year and in renal transplant patients was normal. 3. The seasonal variation of plasma 25-hydroxy-vitamin D concentration found in the 58 patients on maintenance haemodialysis for more than 2 years is similar to that reported in normal subjects.

scholarly journals Comparison of a magnetic retrieval device vs. flexible cystoscopy for removal of ureteral stents in renal transplant patients: A randomized controlled trial

2020 ◽  
Vol 15 (2) ◽  
Author(s):  
Anil Kapoor ◽  
Jason Akerman ◽  
Emily Wong ◽  
Gaurav Vasisth ◽  
Fadil Hassan ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Renal Transplant ◽  
Controlled Trial ◽  
Ureteral Stent ◽  
Flexible Cystoscopy ◽  
Stent Removal ◽  
Transplant Patients ◽  
Renal Transplant Patients ◽  
Tract Infections ◽  
Retrieval Device

Introduction: Placement of a ureteral stent at the time of renal transplantation can reduce complications when compared to non-stented anastomoses. Removal by flexible cystoscopy can be associated with discomfort, risk for infection, and high costs. New magnetic stents offer a means of bypassing cystoscopy by use of a magnetic retrieval device. Our objective was to compare clinical and cost-related outcomes of conventional and magnetic stents in patients undergoing deceased donor renal transplantation. Methods: Patients were randomized to receive either a conventional or a Black-Star® magnetic stent. Clinical, procedural, and cost outcomes were assessed, and the Ureteral Stent Symptom Questionnaire (USSQ) was administered with the stent in situ and after stent removal. All variables were compared between groups. Results: Forty-one patients were randomized to conventional (n=19) or Black-Star (n=22) stent. The total time for stent removal under cystoscopy was significantly longer compared to Black-Star removal (6.67±2.47 and 4.80±2.21 minutes, respectively; p=0.019). No differences were found in the USSQ domains between groups. Rates of urinary tract infections and surgical complications between groups were similar. Stent removal was well-tolerated in both groups. Black-Star stent use resulted in a cost savings of $304.02 Canadian dollars (CAD) per case. Conclusions: USSQ scores suggest that stent removal with the Black-Star magnetic stent is as equally well-tolerated as flexible cystoscopy by renal transplant patients. Black-Star stent removal was significantly faster than conventional stents. No differences in discomfort, infection rate, or complication rate were found. Use of the Black-Star stent resulted in an estimated annual savings of $27 360 CAD at our centre.

Sign in / Sign up

Export Citation Format

Share Document